Alector, Inc. ALEC
At closeNov 4, 2026, 5:19 AM EST
Pre-market · Nov 4, 5:19 AM ET
- YTD
- +31.41%
- 1 year
- +55.30%
- Market cap
- 228.90M
- Revenue (ttm)
- 61.51M
- Profit margin
- -257.54%
- EPS (ttm)
- -1.04
- Shares out
- 97.93M
- Forward P/E
- -1.25
- YTD return
- +31.41%
- 1-year return
- +55.30%
- Volume
- 1.43M
- Avg volume
- 3.34M
- Open
- 2.17
- Previous close
- 2.15
- Day's range
- 2.03 – 2.25
- 52-week range
- 1.09 – 2.76
- Beta
- 0.66
- Analysts
- Buy
- Price target
- 5.51 (+168.9%)
- Earnings date
- Aug 7, 2024
2Y -3.22 (-61.10%)
Key statistics
- Enterprise value
- -240.41M
- PEG ratio
- 0.00
- Price / sales
- 2.95
- Price / book
- 1.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 68.40%
- Free cash flow
- -66.92M
- Total cash
- 457.20M
- Total debt
- 34.64M
- Return on equity
- -112.55%
- Short % of float
- 7.83%
- 50-day average
- 3.81
- 200-day average
- 4.92
Analyst view
Consensus: buy
- Target (low)
- 1.00
- Target (mean)
- 5.51
- Target (high)
- 12.00
- Strong buy2
- Buy5
- Hold1
- Sell1
- Strong sell1
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.53686.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.53 | -0.43 | +0.10 | +18.87% |
| Aug 7, 2024 | Jun 1, 2024 | -0.49 | -0.40 | +0.09 | +18.37% |
| Aug 7, 2024 | Jun 1, 2024 | -0.49 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.48 | -0.38 | +0.10 | +20.83% |
| May 8, 2024 | Mar 1, 2024 | -0.48 | — | — | — |
| Feb 27, 2024 | Dec 1, 2023 | -0.80 | -0.49 | +0.31 | +38.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | Stifel | down | Buy | Hold |
| Nov 26, 2024 | Morgan Stanley | down | Equal-Weight | Underweight |
| Nov 26, 2024 | BTIG | main | Buy | Buy |
| Nov 26, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Nov 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 17, 2024 | Cantor Fitzgerald | reit | — | Overweight |
About Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alector.com
News
Will Alector (ALEC) Report Negative Q3 Earnings? What You Should Know 
Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday 
HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $8 
HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $8 
Morgan Stanley Maintains Underweight on Alector, Raises Price Target to $3 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Alector Teams Up With Genentech On Potential Parkinson’s Treatment
Your note
Sign in to keep a note on ALEC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GAROFALO ELIZABETH A. | Director | Stock Award(Grant) | Jun 11, 2024 | 61,250 |
| GRASSO MARC | Chief Financial Officer | Sale | Dec 1, 2024 | 330,651 |
| HAMMOND PAULA | Director | Sale | Aug 11, 2024 | 60,209 |
| KENKARE-MITRA SARASWATI | Officer | Sale | Dec 1, 2024 | 565,215 |
| LAVIGNE LOUIS J JR | Director | Stock Award(Grant) | Jun 11, 2024 | 81,261 |
| ROMANO GARY | Officer | Sale | Dec 1, 2024 | 349,283 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.90% | 14,595,014 | 27.00M | Sep 29, 2024 |
| Blackrock Inc. | 9.55% | 9,352,044 | 17.30M | Sep 29, 2024 |
| Vanguard Group Inc | 5.57% | 5,455,727 | 10.09M | Sep 29, 2024 |
| Deep Track Capital, Lp | 4.73% | 4,631,998 | 8.57M | Sep 29, 2024 |
| Morgan Stanley | 4.45% | 4,355,770 | 8.06M | Sep 29, 2024 |
| JP Morgan Chase & Company | 2.79% | 2,728,823 | 5.05M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 3.71% | 3,637,369 | 6.73M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 3.61% | 3,535,753 | 6.54M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.42% | 2,365,571 | 4.38M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.14% | 2,098,341 | 3.88M | Oct 30, 2024 |
| JP Morgan Small Cap Growth Fund | 1.54% | 1,506,611 | 2.79M | Sep 29, 2024 |
| Fidelity Growth Company K6 Fund | 1.30% | 1,268,931 | 2.35M | Oct 30, 2024 |